10919 results about "Immunology" patented technology

The invention provides an anti-human serum albumin nano antibody and application thereof, and belongs to the technical field of antibodies. The invention provides an anti-human serum albumin nano antibody HSA-32 with relatively high affinity, and the anti-human serum albumin nano antibody HSA-32 is subjected to humanized transformation, so that three obtained humanized anti-human serum albumin nano antibodies can be used for reducing the immunogenicity of the HSA-32 and improving the immunogenicity of the HSA-32; and high specificity and high affinity of combination with the human serum albumin and stability and solubility of the antibody are maintained. The anti-human serum albumin nano antibody can be used for separation, purification and detection of human serum albumin and separation and purification of polypeptide, protein or antibody drugs fused with the anti-human serum albumin nano antibody. Meanwhile, the anti-human serum albumin nano-antibody can effectively prolong the half-life period of polypeptide, protein and antibody drugs fused with the anti-human serum albumin nano-antibody, and can be used for developing long-acting polypeptide, protein or antibody drugs.

The invention provides application of an SRC inhibitor combined with a KRAS-G12C inhibitor to preparation of a medicine for treating KRAS-G12C mutant lung cancer and a medicine composition, and relates to the technical field of biological medicine, compared with independent use of the KRAS-G12C inhibitor, the scheme of the SRC inhibitor combined with the KRAS-G12C inhibitor can effectively inhibit proliferation and survival of KRAS-G12C mutant lung cancer cells, and the application of the SRC inhibitor combined with the KRAS-G12C inhibitor to preparation of the medicine for treating the KRAS-G12C mutant lung cancer can be used for preparing the medicine for treating the KRAS-G12C mutant lung cancer. The compound can effectively inhibit the activation of a KRAS-MARK pathway and an SRC-FAK pathway, the combination of the compound and the compound has a synergistic anti-tumor effect, and the compound and the compound can be directly combined for medication, can also be prepared into a combined preparation for treating KRAS mutant lung cancer, and have a good clinical transformation prospect.

The present disclosure relates generally to methods for treating cancer with a KRAS inhibitor in combination with an immune checkpoint inhibitor, and more specifically to treating cancer with a pyridopyrimidine derivative in combination with a PD-1 or PD-L1 inhibitor.

This disclosure relates to homodimeric antibodies for use in treating cancer generally and to both homodimeric antibodies that bind human sperm protein 17 (Sp17) and homodimeric antibody immunoconjugates specifically. Such homodimeric antibodies display improved properties relative to monomeric antibodies, for example, because they can crosslink cells, improve cellular uptake, and / or carry greater payloads.

Described herein are methods and systems for a conversational assistant that may be configured for use with one or more applications. The disclosed systems and methods may be configured as an outer loop / inner loop architecture incorporating one or more large language models (LLMs) and / or RAG functionality to support dialog-based interactions.

Provided herein are antibodies that specifically bind to MICA / B having a heavy chain, a light chain, a variable heavy chain domain (VH), a variable light chain domain (VL), and a complementarity determining region (CDR) disclosed herein, as well as methods and uses thereof.

The invention provides compositions and methods for treating diseases such as cancer. The invention also relates to a method of administering a therapy comprising a chimeric antigen receptor, an IL-15R molecule and an IL-15 molecule.

The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.

A method for configuring a subsequent conditional primary secondary cell addition / change (S-CPAC) to a UE is provided. The method receives from a source cell an S-CPAC configuration that includes an RRC configuration for a primary secondary cell (PSCell) and a set of conditions for switching to the PSCell. The method receives a secondary key (SK)-counter list associated with the S-CPAC. The list includes one or more SK-counter entries arranged in an order. The method stores the S-CPAC configuration and the SK-counter list. After determining that one or more of the set of conditions are satisfied, the method selects a first SK-counter entry of the SK-counter list and configures the UE with the S-CPAC configuration to switch from another PSCell to the PSCell. In configuring the UE with the S-CPAC configuration, the first SK-counter entry is applied. The method then removes the first SK-counter entry from the SK-counter list.

The present disclose includes, among other things, methods of treating or lessening the severity of CFTR-mediated disease or disorders.

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

The present invention belongs to the field of biological detection technology, and specifically relates to an anti-monkey C-reactive protein monoclonal antibody, an enzyme-linked immunosorbent assay kit and its application. Named CRP-13, CRP-13 includes a heavy chain variable region and a light chain variable region; the heavy chain variable region has three complementary determining regions CDR-H1 to CDR-H3, and the amino acid sequences are shown in SEQ ID NO.6-SEQ ID NO.8; the light chain variable region has three complementary determining regions CDR-L1 to CDR-L3, and the amino acid sequences are shown in SEQ ID NO.9-SEQ ID NO.11. The monoclonal antibody of the present invention can specifically bind to monkey C-reactive protein with high specificity. The above monoclonal antibody can be used to screen a paired monoclonal antibody, and a monkey C-reactive protein enzyme-linked immunosorbent assay kit is obtained based on the combination of the monoclonal antibodies, which can detect the content of monkey C-reactive protein in monkey serum, plasma or tissue fluid.

The invention provides cat serum albumin and application thereof, and relates to the technical field of protein engineering. According to the invention, mutation is carried out on the cat serum albumin for the first time to obtain a beneficial mutation site, so that the cat serum albumin mutant which can be highly expressed in a pichia pastoris system is obtained. In addition, the cat serum albumin mutant I31L also has the effect of treating ascites due to cirrhosis, and the treatment effect is obviously higher than that in the prior art. A new biological material is provided for application of the cat serum albumin, and a foundation is laid for genetic engineering modification of the cat serum albumin.

The invention belongs to the field of antibodies, and particularly relates to an anti-NMP22 monoclonal antibody as well as a preparation method and application thereof. The invention provides CDR sequences of a heavy chain variable region and a light chain variable region of an anti-NMP22 antibody, the antibody can specifically recognize nuclear matrix protein 22 (NMP22), has high affinity and high specificity to the protein, can be applied to diagnosis of diseases related to abnormal urine nuclear matrix protein 22 level, and especially can be applied to clinical diagnosis of bladder cancer.

Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.

The present disclose includes, among other things, methods of treating or lessening the severity of CFTR-mediated disease or disorders.

The present application provides anti-B7-H3 monoclonal antibodies, in particular, high affinity B7-H3 humanized monoclonal antibodies having cross-activity with humans, cynomolgus monkeys and mice, as well as nucleic acids encoding the antibodies, vectors comprising the nucleic acids, and host cells comprising the nucleic acids or vectors. Also disclosed are pharmaceutical compositions and conjugates comprising the antibodies, as well as uses of the antibodies.

The invention relates to application of a targeted inhibition circPDK1 reagent in preparation of an anti-esophageal cancer drug, and belongs to the field of biological medicines. The reagent for targeted inhibition of circPDK1 expression provided by the invention is shRNA or siRNA, and in-vivo and in-vitro experiments prove that the reagent can significantly inhibit circPDK1 expression and inhibit growth and migration of esophageal cancer tumor cells; after siRNA of targeted annular circPDK1 is packaged into efficient and low-toxicity LNP-siRNA, circPDK1 expression is specifically silenced, proliferation and migration of esophageal cancer tumors can be remarkably inhibited, and a basis is provided for clinical treatment and scientific research of esophageal cancer related circRNA.

The invention discloses an N-sugar chain marker combination for predicting the curative effect state of IgA and IgG type MM and a prediction scoring system and application of the N-sugar chain marker combination. The N-sugar chain marker combination is composed of the following 11 N-sugar chains: NGA2, NGA2F, NG1A2F-1, NG1A2F-2, NA2, NA2F, NA2FB, NA3, NA3Fb, NA4 and NA4Fb. The method has the advantages that (1) the relevance between the N-carbohydrate chain and the curative effect in the blood of the IgA and IgG type MM patients in different curative effect states is found for the first time, and the N-carbohydrate chain can be used as an index for predicting the curative effect states of the IgA and IgG type MM patients for the first time; and (2) the N-carbohydrate chain curative effect prediction scoring system provided by the invention is used for predicting the curative effect states of IgA and IgG type MM patients, and a new technical means is provided for predicting the curative effects of the IgA and IgG type MM patients.

The invention discloses application of an MCU (microprogrammed control unit) inhibitor in preparation of a medicine for preventing or treating intestinal ischemia-reperfusion injury, and relates to the technical field of biological medicine, and the MCU inhibitor comprises one or two of a reagent for inhibiting MCU gene expression and a reagent for inhibiting MCU protein activity. The MCU inhibitor disclosed by the invention is beneficial to relieving intestinal mucosa injury and inflammatory change of intestinal tissues, improving completeness of a villus structure, reducing pathological injury degree score of the intestinal tissues and relieving cell apoptosis degree in the intestinal tissues, so that the MCU inhibitor is beneficial to relieving programmed death of intestinal mucosa cells; as a main component, the pharmaceutical composition is beneficial for preventing or treating intestinal ischemia-reperfusion injury.

The invention discloses an application of an inhibitor aiming at T cell TIGIT in preparation of an anti-tuberculosis drug. The inhibitor comprises an Ociperlimab (Ociperlimab), an AGEN1777 (AGEN1777), a Tiragolumab (Tiragolumab) and the like. The TIGIT on the surface of the T cell is blocked, the T cell is promoted to increase the capacity of eliminating intracellular bacteria of macrophages by up-regulating MPEG1, the proliferation of tubercle bacillus is controlled, and evidence is provided for developing antituberculous drugs.

The invention provides recombinant VIII type humanized collagen and application thereof, and the recombinant VIII type humanized collagen is of a triple helix structure, has good cell adhesion activity, does not generate immunological rejection and anaphylactic reaction when being applied to a human body, is a brand new human body synthetic biological material, and has good application prospects.

The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of use for delivery of cargo to brain tissue. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.

To meet the need of a novel therapy for preventing or treating pathological dysbiosis of the gut microbiota, in particular for treating or preventing neurodegenerative diseases or bowel diseases. The present invention relates to the use of a composition comprising a plurality of specific molecules for the treatment of a pathological dysbiosis of the gut microbiota. The pathological dysbiosis of the gut microbiota may be characterized by an excess amount of sulfide-producing bacteria and insufficient butyrate-producing bacteria.

This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and / or PD-L1.

The invention relates to the field of antibodies, in particular to an anti-human IgE antibody and application thereof. The CDR of a heavy chain variable region in the anti-human IgE antibody provided by the invention comprises a CDR-H1 of which the amino acid sequence is shown as SEQ ID No. 1 or SEQ ID No. 7, a CDR-H2 of which the amino acid sequence is shown as SEQ ID No. 2 or SEQ ID No. 8, and a CDR-H3 of which the amino acid sequence is shown as SEQ ID No. 3 or SEQ ID No. 9; the CDR of a light chain variable region in the anti-human IgE antibody comprises a CDR-L1 of which the amino acid sequence is as shown in SEQ ID No. 4 or SEQ ID No. 10, a CDR-L2 of which the amino acid sequence is as shown in SEQ ID No. 5 or SEQ ID No. 11, and a CDR-L3 of which the amino acid sequence is as shown in SEQ ID No. 6 or SEQ ID No. 12. The antibody provided by the invention is high in affinity and high in sensitivity, can detect human IgE with the concentration of 0.02 IU / mL, and has clinical diagnostic significance for identifying anaphylactic reaction.

The invention relates to anti-drug neutralizing antibody analysis. In particular, the present application relates to methods for detecting neutralizing antibodies against a vascular endothelial growth factor (VEGF) binding moiety and a programmed cell death ligand-1 (PD-L1) binding moiety in a biological sample from an individual administered a bispecific antibody drug comprising the VEGF binding moiety.

The invention discloses stem cell culture equipment, and relates to the technical field of cell culture equipment, the stem cell culture equipment comprises a culture box, a rotating disc and a culture dish, horizontal plates are arranged in the middle of the culture box at equal intervals, and the middle of each horizontal plate is connected with the rotating disc through a bearing. The stem cell culture equipment is provided with a switching mechanism and an anti-deviation mechanism, a limiting ring and a circular track are separated, a conical block drives a tray to push culture dishes to be rapidly taken and placed, a rotating disc rotating slowly facilitates personnel to take or place the culture dishes one by one at the position close to an opening of a culture box, the limiting ring and the circular track are in matched butt joint, and the operation is convenient. The extrusion part elastically extrudes the culture dish on the tray when reversely moving and overturning, and meanwhile, the traction balance wheel is propped against the upper edge of a sealing end cover of the culture dish, so that the culture equipment can prevent the culture dish which is rotationally placed from shaking and shifting, and can be used for lifting and ejecting all the culture dishes at one time when the culture dish is taken out; and the operation of manually placing the culture dishes can also be reduced.